Canopy Growth Corp., Smith Falls, Ont., has signed a deal with the Victorian State Government to further develop research and technical capabilities in the production of medical cannabis in Australia. The research agreement between Canopy Growth and Australia’s department of agriculture will focus on medical applications for cannabis genetics, strain development, cultivation, and processing.
Stabilized cannabis genetics from Canopy Growth’s Canadian operations have already been successfully imported into the country and are growing in the state of Victoria.
“This agreement allows us to combine our expertise in medical cannabis with the world-leading bioscience research capabilities of Agriculture Victoria,” said Mark Zekulin, president, Canopy Growth. “With this important MOU, we hope to increase innovation and institutional understanding in the Australian medical cannabis market to ensure that our globally recognized genetics are available in Australia for research and commercial purposes.”
Victoria was the first state in Australia to legalize access to medical cannabis for patients in the region, and the state will use its bioscience research capabilities to work with Canopy Growth to identify and develop optimal plant strains for a range of therapeutic uses. Specific capabilities include genome sequencing, comprehensive metabolome analysis and chemo-typing, as well as technologies for accelerated precision breeding.
Canopy Growth has emerged as the world’s largest cannabis company.